HELEN SOLIMAN: Open Payments
NPI 1245798404 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$985 in 43 payments from 18 companies in 2025. Trend: 2023 $1,076 · 2024 $1,568 · 2025 $985
Food & beverage: $985
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $310 |
| UCB, Inc. | 4 | $111 |
| Biogen, Inc. | 3 | $88 |
| EMD Serono, Inc. | 3 | $72 |
| Lilly USA, LLC | 3 | $61 |
| Neurocrine BioSciences, Inc. | 2 | $57 |
| Novartis Pharmaceuticals Corporation | 2 | $35 |
| Amgen Inc. | 2 | $34 |
| TG Therapeutics, Inc. | 1 | $31 |
| SK Life Science, Inc. | 1 | $28 |
Products named: QULIPTA, BOTOX, Briviact, KISUNLA, AVONEX, INGREZZA, KESIMPTA, UPLIZNA.
Industry payments across IN — which companies pay providers there.
